Unclassified · NSE: TORNTPHARM
Torrent Pharmaceuticals share analysis
Fair value, business quality, the case for and against, and the risks — computed by VestCall from reported data, updated 14 October 2026.
Torrent Pharmaceuticals in one paragraph
Torrent Pharmaceuticals (NSE: TORNTPHARM) was trading at ₹4,577.1 on 14 October 2026. VestCall scores its business health 75/100 (healthy). On valuation, the price sits in the “Valuation Premium” zone (₹4,565.22 and above) — above the modelled fair-value range. This is a reading of the evidence, not a buy or sell recommendation.
- Share price₹4,577.1
- Business health75/100
- Growth73/100
- Financial strength65/100
- Valuation12/100 · Fair
- Valuation zoneValuation Premium
- RiskMedium
Is Torrent Pharmaceuticals overvalued or undervalued?
At ₹4,577.1, Torrent Pharmaceuticals sits in VestCall’s “Valuation Premium” zone (₹4,565.22 and above): above the modelled fair-value range. Its valuation scores 12/100 (fair) against Unclassified peers. Zones describe where the price sits against modelled value; they are not an instruction to buy or sell.
| Valuation zone | Price band | What it means |
|---|---|---|
| Deeply Discounted | ₹4,007.32 – ₹4,240.3 | Furthest below the modelled fair-value range |
| Attractive Valuation | ₹4,240.3 – ₹4,443.16 | Below the modelled fair-value range |
| Fairly Valued | ₹4,443.16 – ₹4,565.22 | Inside the modelled fair-value range |
| Valuation Premium (current) | ₹4,565.22 and above | Above the modelled fair-value range |
The case for and against Torrent Pharmaceuticals
What supports the case
- Capital Allocation · 100/100.
- Business Quality · 86/100.
- Growth · 73/100.
- Management Stability · 67/100.
- Financial Strength · 65/100.
- Shareholding Quality · 64/100.
What needs proof
No measured pillar is currently below the strong range.
Torrent Pharmaceuticals key ratios
| Ratio | Torrent Pharmaceuticals | Unclassified median |
|---|---|---|
| P/E | 20.68x | — |
| P/B | 5.92x | — |
| P/S | 3.6x | — |
| Return on equity (ROE) | 25.3% | — |
| Return on capital employed (ROCE) | 34.0% | — |
| Operating margin | 20.7% | — |
| Net margin | 15.4% | — |
| Current ratio | 1.07x | — |
Torrent Pharmaceuticals growth
Growth scores 73/100, with a positive trend, measured Mar 2023 to Mar 2026.
| Measure | Reading |
|---|---|
| Revenue CAGR | 12.8% |
| Net profit CAGR | 19.8% |
| EPS CAGR | 20.2% |
| Revenue growth, latest year | 20.3% |
| Profit growth, latest year | 11.9% |
Torrent Pharmaceuticals bull, base and bear case
Modelled annual return under three sets of stated assumptions over 5 years. These are model outputs, not a forecast or a promise of return.
| Scenario | Modelled CAGR | Weight | Assumption |
|---|---|---|---|
| Bear | +1.5% | 19% | Growth decelerates to 5.5% and the multiple de-rates toward the cohort's trough. |
| Base | +15.2% | 55% | Earnings compound near the measured 15.2% and the multiple drifts toward its quality-adjusted warranted level. |
| Bull | +24.7% | 26% | Growth holds at 21.2% and the market pays the full premium the measured quality supports. |
Risks to watch in Torrent Pharmaceuticals
| Review trigger | Current | Threshold | Status |
|---|---|---|---|
| Promoter holding drops materially | 60.78% | below 65.31%, 3 points under the Jun 2026 filing | high · breached |
| Return on equity falls below the quality floor | 25.3% | below 15% | high · armed |
| Revenue growth falls below the thesis floor | 12.84% | below 8% | high · armed |
| Price runs more than two sigma above its own trend | 4577.1 | at or above 6261.02 | medium · armed |
| Drawdown from the 52-week high exceeds tolerance | 10.65% | at or beyond 25% | low · armed |
| Leverage doubles from the level underwritten today | No leverage line in the balance sheet | unavailable | high · unmeasurable |
| Promoter pledge rises above tolerance | No pledge disclosed (the NSE filing for TORNTPHARM could not be read either (nse_session_unavailable)) | above 10% | high · unmeasurable |
| Valuation reaches the top of its own cohort | No cohort multiple to rank against | at or above the 95th percentile | medium · unmeasurable |
An armed trigger is watched and has not fired; a breached one has.
How Torrent Pharmaceuticals shares have traded
| Measure | Reading |
|---|---|
| 52-week range | ₹3,518.2 – ₹5,122.8 |
| Distance from 52-week high | −10.7% |
| Return, 3 months | −8.0% |
| Return, 12 months | +29.8% |
| Trend | Uptrend |
| Annualised volatility | 22.5% |
| Deepest drawdown, 2 years | −17.6% |
Questions about Torrent Pharmaceuticals shares
Is Torrent Pharmaceuticals overvalued or undervalued?
At ₹4,577.1, Torrent Pharmaceuticals sits in VestCall’s “Valuation Premium” zone (₹4,565.22 and above): above the modelled fair-value range. Its valuation scores 12/100 (fair) against Unclassified peers. Zones describe where the price sits against modelled value; they are not an instruction to buy or sell.
Is Torrent Pharmaceuticals fundamentally strong?
VestCall scores Torrent Pharmaceuticals’s business health 75/100 (healthy). The strongest measured pillars are capital allocation and business quality. Each pillar is computed from reported financials, and a pillar whose inputs were not reported is excluded rather than scored as zero.
What is Torrent Pharmaceuticals’s P/E ratio?
Torrent Pharmaceuticals trades at a P/E of 20.68x, on VestCall’s latest read. A multiple only means something against the business it buys: the quality-adjusted fair value on this page weighs it against Torrent Pharmaceuticals’s returns and growth.
What are the risks of investing in Torrent Pharmaceuticals?
The review triggers VestCall watches for Torrent Pharmaceuticals are: promoter holding drops materially (promoter holding below 65.31%, 3 points under the Jun 2026 filing); return on equity falls below the quality floor (roe below 15%); revenue growth falls below the thesis floor (revenue cagr below 8%). A trigger is a named condition that would change the reading, published so the case against the stock is as visible as the case for it.
Is this a recommendation to buy or sell Torrent Pharmaceuticals?
No. VestCall states where Torrent Pharmaceuticals’s price sits against modelled value, what supports the case and what would break it, with every figure sourced. It does not issue buy, sell or hold calls or price targets. Vestmind is not a SEBI-registered investment adviser or research analyst, and nothing on this page is personalised investment advice.
Compare with other companies in Healthcare
Read the full Torrent Pharmaceuticals analysis
Every score opens into its signals, the valuation into its anchors and workings, and the statements are one click away. Free, no account needed.